Bodo Kirsch

Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial

Ashkan Shoamanesh, Hardi Mundl, Eric E. Smith et al. · The Lancet · 2022 · 193 citations · Full text

Medicine, Neurology, Pharmacology +11

Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF)

Gregory Y.H. Lip, Christoph Hammerstingl, Riccardo Cappato et al. · American Heart Journal · 2016 · 186 citations · Full text

Medicine, Cardiology, Pharmacology +17

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

Sunil V. Rao, Bodo Kirsch, Deepak L. Bhatt et al. · Circulation · 2022 · 148 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial

Robert G. Hart, Mukul Sharma, Hardi Mundl et al. · European Stroke Journal · 2016 · 98 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Dienogest 2 mg Daily in the Treatment of Adolescents with Clinically Suspected Endometriosis: The VISanne Study to Assess Safety in ADOlescents

Andreas D. Ebert, Liying Dong, Martin Merz et al. · Journal of Pediatric and Adolescent Gynecology · 2017 · 97 citations · Full text

Medicine, Endocrinology, Gynecology +16